Protects against all severities of pertussis
- DAPTACEL vaccine has demonstrated efficacy against laboratory-confirmed pertussis with as little as one day of cough in a rigorously designed, NIH*-sponsored pivotal trial (n=2587)1
- 78% >1 day of cough
- 85% >21 days of cough
- The adverse reaction profile of DAPTACEL vaccine is comparable to that of the DT placebo 1
*NIH=National Institutes of Health.
DAPTACEL vaccine is indicated for active immunization against diphtheria, tetanus, and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday).
The most common local and systemic adverse reactions to DAPTACEL vaccine include injection site redness, swelling, and tenderness; fever, irritability, drowsiness, and crying more than usual. Other adverse reactions may occur. DAPTACEL vaccine is contraindicated in persons with a hypersensitivity to any component of the vaccine. In addition, it is contraindicated in persons with any immediate anaphylactic reaction or encephalopathy not attributable to another identifiable cause after a previous dose of DAPTACEL vaccine. Vaccination with DAPTACEL vaccine may not protect all individuals.
Before administering DAPTACEL vaccine, please see full prescribing information.
*DTaP = Diphtheria, tetanus, and acellular pertussis.
Reference: 1. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a
two-component acellular, a five-component acellular, and a whole-cell pertussis
vaccine. N Engl J Med. 1996;334:349-355.